Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular
Free webinar: Telepathology: is there added value in LMICs?
Free webinar: Telepathology: is there added value in LMICs?

Disruption of BAFF-BCR crosstalk in CLL

Dr Alexey Danilov - Knight Cancer Institute, Portland, USA
Disruption of BAFF-BCR crosstalk in CLL ( Dr Alexey Danilov - Knight Cancer Institute, Portland, USA )
24 Jun 2017

Phase Ib/II study of nivolumab in combination with azacytidine in patients with relapsed AML

Prof Naval Daver - MD Anderson Cancer Center, Houston, USA
Phase Ib/II study of nivolumab in combination with azacytidine in patients with relapsed AML ( Prof Naval Daver - MD Anderson Cancer Center, Houston, USA )
24 Jun 2017

Metabolic adaptations to targeted therapy in FLT3 mutated acute myeloid leukaemia

Dr Paolo Gallipoli - University of Cambridge, Cambridge, UK
Metabolic adaptations to targeted therapy in FLT3 mutated acute myeloid leukaemia ( Dr Paolo Gallipoli - University of Cambridge, Cambridge, UK )
24 Jun 2017

Safety and efficacy of blinatumomab for acute lymphoblastic leukaemia

Dr Max Topp - University of Wurzburg, Wurzburg, Germany
Safety and efficacy of blinatumomab for acute lymphoblastic leukaemia ( Dr Max Topp - University of Wurzburg, Wurzburg, Germany )
24 Jun 2017

Blood thinners a risk with cancer-associated venous thromboembolism

Dr Alejandro Lazo-Langner - Department of Medicine, Western University, London, Ontario, Canada
Blood thinners a risk with cancer-associated venous thromboembolism ( Dr Alejandro Lazo-Langner - Department of Medicine, Western University, London, Ontario, Canada )
24 Jun 2017

TGR-1202, ublituximab and ibrutinib combination for advanced CLL and NHL

Dr Loretta Nastoupil - MD Anderson Cancer Center, Houston, USA
TGR-1202, ublituximab and ibrutinib combination for advanced CLL and NHL ( Dr Loretta Nastoupil - MD Anderson Cancer Center, Houston, USA )
24 Jun 2017

FDG-PET guidance allows substantial chemoreduction in Hodgkin lymphoma

Dr Peter Borchmann - Uniklinik Koeln, Cologne, Germany
FDG-PET guidance allows substantial chemoreduction in Hodgkin lymphoma ( Dr Peter Borchmann - Uniklinik Koeln, Cologne, Germany )
24 Jun 2017

ZUMA 1: CD19 CAR T cells for refractory NHL

Dr Yi Lin, Mayo Clinic - Rochester, MN, USA
ZUMA 1: CD19 CAR T cells for refractory NHL ( Dr Yi Lin, Mayo Clinic - Rochester, MN, USA )
24 Jun 2017

Risk and benefit of anti-coagulants for elderly patients with cancer-associated venous thromboembolism

Dr Alejandro Lazo-Langner - Department of Medicine, Western University, London, Ontario, Canada
Risk and benefit of anti-coagulants for elderly patients with cancer-associated venous thromboembolism ( Dr Alejandro Lazo-Langner - Department of Medicine, Western University, London, Ontario, Canada )
24 Jun 2017

Interim analysis of the JULIET study

Prof Gilles Salles - Université Claude Bernard, Lyon, France
Interim analysis of the JULIET study ( Prof Gilles Salles - Université Claude Bernard, Lyon, France )
24 Jun 2017

ZUMA1 trial of CD19 CAR T cells for aggressive NHL

Dr Yi Lin - Mayo Clinic, Rochester, USA
ZUMA1 trial of CD19 CAR T cells for aggressive NHL ( Dr Yi Lin - Mayo Clinic, Rochester, USA )
24 Jun 2017

400mg imatinib as good as 800mg for 10 year CML survival

Prof Rüdiger Hehlmann - European LeukemiaNet, Mannheim, Germany
400mg imatinib as good as 800mg for 10 year CML survival ( Prof Rüdiger Hehlmann - European LeukemiaNet, Mannheim, Germany )
23 Jun 2017

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation